In this meta-analysis, we found that patients with localized or locally advanced nonmetastatic, high-grade prostate cancer with low PSA levels (<4 ng/mL) had a nonsignificant reduction in the risk of both PCSM and ACM when docetaxel was added to the SOC therapies of testosterone suppression plus radiotherapy or RP. Here, KLK3 is linked to prostate cancer.